ArticleDiscover mental health2025
The impact of epidermolysis bullosa on quality of life and mental health.
Article in Discover mental health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Health-related quality of life in recessive dystrophic epidermolysis bullosa: findings of the Prospective Epidermolysis Bullosa Longitudinal Evaluation Study (PEBLES).Orphanet journal of rare diseases · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEpidermolysis bullosa (EB) is a rare, chronic, incurable, multisystemic genetic disorder characterized by skin fragility, resulting in blistering from minimal trauma or spontaneously. Despite its physical impact, little is known about the mental health and quality of life (QoL) of those affected. This study aims to investigate these aspects in individuals with EB.
methodsA cross-sectional study was conducted in Brazil using a self-administered questionnaire and a convenience sample. Data on clinical-epidemiological characteristics, QoL (DLQI-BRA and QoLEB), and depression indicators (PHQ-9) were collected. Descriptive statistics and the Chi-square test were used, with a significance level of p < 0.05.
resultsThe sample consisted of 31 patients, predominantly women (89.3%), with a mean age of 33.32 ± 11.3 years. The recessive dystrophic subtype was most common (54.8%), and depressive symptoms were present in 71%. PHQ-9 results revealed 29% had "mild depression," 16.1% "moderate depression," 22.6% "moderately severe depression," and 3.2% "severe depression." QoLEB indicated significant impairment in functional domains, while DLQI showed that 45.2% of patients experienced severe QoL impact. The most affected domains were leisure, symptoms and feelings, and daily activities.
conclusionThe findings highlight the substantial impact of EB on mental health, QoL, and personal relationships. These results reinforce the need for early mental health screening and the integration of multidisciplinary care to optimize patient outcomes. Implementing structured psychological support, along with comprehensive dermatological and medical management, could mitigate the burden of the disease and enhance the overall well-being of affected individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.